glp-1 gip therapies weight management effectiveness TrimRX Optimizing GLP-1 therapies for obesity

10.1016/j.bbr.2015.07.024 Behav

[DOI] [PubMed] [Google Scholar] 66.Chao A.M., Wadden T.A., Walsh O.A., Gruber K.A., Alamuddin N., Berkowitz R.I., Tronieri J.S

At the American College of Cardiology meetings today, with simultaneous publication in NEJM, was a new randomized trial of semaglutide in 616 participants with heart failure with preserved ejection fraction, obesity and Type 2 diabetes

11 In clinical trials, exenatide has demonstrated efficacy in terms of both improved glycemic control and appetite suppression leading to weight loss

Goes beyond appetite suppression to influence glucose metabolism and energy utilization creating a favorable environment for sustained weight loss